English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

This is an observational, longitudinal and retrospective study of a group of patients with moderate to severe plaque psoriasis whom had been treated with efaluzimab (1mg/Kg/week) for up to 20 weeks. Nevertheless, first dose of 0.7 mg/kg was given. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), the body surface area (BSA) and index of the quality of life (DLQI). A statically significant improvement was observed in the PASI, BSA and DLQI after 4, 12 and 20 weeks of therapy. After 20 weeks of treatment, the PASI 75 and 90 values were 100% and 97% respectively. When it comes to safety, efaluzimab was well tolerated and no remarkable side effects were recorded.

Efalizumab in Psoriasis: Our Experience with 11 Patients~!2010-01-28~!2010-05-10~!2010-06-11~!